Drug Patent Watch

DECEMBER 10, 2024

This shift has led to the emergence of integrated contract development and manufacturing organizations (CDMOs), which provide end-to-end support for drug developers. from 2023 to 2030. from 2023 to 2030. Reshaping drug development through CRO/CDMO integration. References Patheon. 2023, August 31).

Drug Development 96

Drug Development Compliance Pharmaceutical Companies Drugs 96

PPD

OCTOBER 18, 2023

Continued expansion of the biotech industry is occurring in parallel, with an estimated compound annual growth rate of 13.96% from 2023-2030. 1 With this growth comes increased demands for laboratory services at all steps across the development process.

Laboratories 52

Laboratories Assay Development Small Molecule Drug Development 52

DrugBank

MARCH 7, 2024

As we step into 2024, the momentum is expected to continue, with analysts projecting the weight loss drug market to reach remarkable heights, potentially hitting $100 billion by the end of the decade. adults using obesity medications by 2030, further underlining the growing significance of this sector.

Pharmaceutical Companies 98

Pharmaceutical Companies Clinical Trials Pharmaceuticals Therapies 98

Vial

MAY 20, 2024

Clinical CROs in Clinical Research Randomized clinical trials are the gold-standard of evidence-based medicine, representing the culmination of the long, arduous drug development pipeline. The two broadest categories of drug development can be separated into the preclinical and clinical research stages. over this period.

Clinical Research 52

Clinical Research Clinical Trials Research Trials 52

Vial

FEBRUARY 15, 2024

over the forecast period (2022-2030). Expertise in regulatory compliance : With deep regulatory knowledge, CROs assist sponsors in obtaining regulatory approvals, ensuring compliance with local regulations, and managing interactions with regulatory authorities.

Pharma Companies 52

Pharma Companies Clinical Trials Compliance Trials 52

DrugBank

FEBRUARY 19, 2025

The application of Artificial Intelligence (AI) in drug discovery is rapidly transforming the pharmaceutical industry, offering opportunities to accelerate the identification of novel therapeutic targets, optimize molecule design, and enhance clinical trial efficiency. billion in 2023 to $7.9

Clinical Trials 52

Clinical Trials Drugs Trials Treatment 52

Perficient: Drug Development

NOVEMBER 15, 2024

election results could significantly shift healthcare policy and impact healthcare access, affordability, regulation, and innovation. billion by 2030. Strict regulations around HIPAA, PHI, and PII create significant barriers, making it difficult to adopt off-the-shelf AI solutions from fields like commerce or digital experience.

Regulations 64

Regulations Compliance Production Nurses 64